Sandoz shares plunged Wednesday on their market debut after the generic and biosimilar drugmaker’s value was measured at a lower-than-expected 10.3 billion Swiss francs ($11.2
Sandoz shares plunged Wednesday on their market debut after the generic and biosimilar drugmaker’s value was measured at a lower-than-expected 10.3 billion Swiss francs ($11.2